Filters








24 Hits in 10.8 sec

Multi-label Inductive Matrix Completion for Joint MGMT and IDH1 Status Prediction for Glioma Patients [chapter]

Lei Chen, Han Zhang, Kim-Han Thung, Luyan Liu, Junfeng Lu, Jinsong Wu, Qian Wang, Dinggang Shen
2017 Lecture Notes in Computer Science  
In this paper, we propose a novel Multi-label Inductive Matrix Completion (MIMC) model, highlighted by the online inductive learning strategy, to jointly predict both MGMT and IDH1 statuses.  ...  Traditionally, the statuses of MGMT and IDH1 are obtained via surgical biopsy, which is laborious, invasive and timeconsuming.  ...  Conclusion In this paper, we focus on addressing the tasks of predicting MGMT and IDH1 statuses for HGG patients.  ... 
doi:10.1007/978-3-319-66185-8_51 pmid:29770368 pmcid:PMC5951635 fatcat:i2ixdg33mnan5gmuwqab6zdxay

EPMA position paper in cancer: current overview and future perspectives

Godfrey Grech, Xianquan Zhan, Byong Chul Yoo, Rostyslav Bubnov, Suzanne Hagan, Romano Danesi, Giorgio Vittadini, Dominic M Desiderio
2015 The EPMA Journal  
During the development of PPPM, many rapid, specific, and sensitive new methods for earlier detection of cancer will result in more efficient management of the patient and hence a better quality of life  ...  At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine (PPPM).  ...  Acknowledgements The authors acknowledge the contribution of Professor Olga Golubnitschaja for the critical discussion and advice in putting together the concept of the Position Paper.  ... 
doi:10.1186/s13167-015-0030-6 pmid:25908947 pmcid:PMC4407842 fatcat:k65bgprkzfawzllhk4i5kulete

Hepatocellular Carcinoma [chapter]

Daniel H. Palmer, Philip J. Johnson
2020 Treatment of Cancer  
patients eligible for radical treatment irrespective of MGMT status.  ...  , and those ineligible for HDMTX-based therapy, i.e., those suitable for palliative treatment. 74 Category 1 patients should be ofered MATRix combination chemotherapy for induction with consideration  ... 
doi:10.1201/9780429026638-9 fatcat:au6qsrzolvbtxfbalffhyv3fp4

American Association of Neuropathologists, Inc. Abstracts of the 87thAnnual Meeting June 23–26, 2011 Seattle, WA

2011 Journal of Neuropathology and Experimental Neurology  
Two proposed mechanisms for the HS-Aging pathology involve aberrant TDP-43 expression and vasculopathy.  ...  Study Y for which the neuropathological analyses were performed at the University of Kentucky.  ...  of Spectral Image Analysis For Prediction of 1p/19q Deletion Status in Gliomas Kimberly Stogner-Underwood, Colleen Jackson-Cook, Carleton Garrett, Hope Richard, Catherine Dumur, Christine Fuller.  ... 
doi:10.1097/nen.0b013e3182227917 fatcat:gtigoq4ag5d7joowcbdsnysmda

American Association of Neuropathologists, Inc.: Abstracts of the 85thAnnual Meeting June 11-14, 2009 San Antonio, Texas

2009 Journal of Neuropathology and Experimental Neurology  
We assessed mutations in the IDH1 gene in 623 gliomas from 562 patients.  ...  Recent advances in therapeutic options have improved survival in ATRT patients with the use of a multi-treatment modality approach.  ... 
doi:10.1097/nen.0b013e3181a407ee fatcat:rhq7jxnojfcqrncfhdrqgytzqa

American Association of Neuropathologists, Inc.: Abstracts of the 86thAnnual Meeting June 10-13, 2010 Philadelphia, PA

2010 Journal of Neuropathology and Experimental Neurology  
H19 hypoxic induction and its tight association with mutant forms of p53 make it an ideal new target for therapy of high grade glioma.  ...  Five tumors showed coexpression of mutant IDH1 and p53. Of the case analyzed, twelve low grade gliomas showed gained of chromosome 7 by FISH analysis and complete results will be presented.  ...  Thus, PlGF targeting may provide a safe and efficient therapy for pediatric medulloblastoma. 160 Utility of the Presence of Brain Tissue as a Surrogate Marker of Brain Invasion in Predicting Recurrence  ... 
doi:10.1097/nen.0b013e3181deb5a1 fatcat:xyiuly7njjfdvgm42s6y4uue4m

An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances

Valentina Tateo, Lisa Manuzzi, Claudia Parisi, Andrea De Giglio, Davide Campana, Maria Abbondanza Pantaleo, Giuseppe Lamberti
2021 Pharmaceuticals  
Thymic tumors are a group of rare mediastinal malignancies that include three different histological subtypes with completely different clinical behavior: the thymic carcinomas, the thymomas, and the rarest  ...  Nowadays, few therapeutic options are available for relapsed and refractory thymic tumors after a first-line platinum-based chemotherapy.  ...  Methylation of MGMT promoter is correlated with a higher sensitivity to alkylating agents in different cancer types, including gliomas, lymphomas, and pancreatic NETs [114] [115] [116] , suggesting a  ... 
doi:10.3390/ph14040316 pmid:33915954 fatcat:bcodghhh2fdk3dn57bw2jbanma

Abstracts of the 35th Annual Meeting of the United Kingdom Environmental Mutagen Society, 16th-18th July 2012 at Swansea University, UK

2012 Mutagenesis  
Immunohistochemical analysis for IDH1 and P53 was carried out on gliomas to correlate these conventional markers with novel spectral biomarkers.  ...  O 6 MeG is repaired by MGMT, which very likely provokes a threshold for mutations and cancer. MGMT also causes a no-effect threshold for cell death.  ...  clinical details of reflux, histology and follow these patients up to assess whether Mn levels might be clinically useful in predicting histology changes.  ... 
doi:10.1093/mutage/ges061 fatcat:ezulnnjj4ne27bjsjb2he7czti

Abstracts DEGRO 2018

2018 Strahlentherapie und Onkologie (Print)  
of glioma patients harboring the IDH1 mutation .  ...  Background and Purpose: The presence of an IDH1 mutation (IDH1R132H) is associated with increased overall survival for patients with glioma .  ...  volume, stage and HPV status)-cohort 1; c) comparison of local tumor control prediction using CT radiomics and PET radiomics-cohort 2 and 3 .  ... 
doi:10.1007/s00066-018-1301-7 pmid:29777265 fatcat:3gtq3dpopzc7pmpc5vrouo43yu

Nemosis [chapter]

Antti Vaheri
2017 Encyclopedia of Cancer  
Adebusola Alagbala Ajibade and Christopher Loo for manuscript editing.  ...  The predictive value of DNA methylation patterns can be best exemplified by the MGMT gene promoter methylation, which has been shown to be predictive of response to alkylating agents and improved clinical  ...  A correct clinicopathological evaluation may predict the clinical behavior and is essential for the management of patients.  ... 
doi:10.1007/978-3-662-46875-3_4002 fatcat:xt3vgg7pyjes5hmumo2qkyhlni

Prognostic and therapeutic implications of migrating tumor cells in glioblastomas

Arnon Møldrup Knudsen
2021
Jeanette Krogh Petersen for assistance with reclassification of the patient cohort according to the 2016 WHO classification.  ...  I owe my gratitude to the Department of Pathology, Odense University Hospital, for Acknowledgements The authors would like to thank technician Helle Wohlleben for her excellent laboratory work, and M.D  ...  (C) Cox-regression including patients with an un-methylated MGMT-promoter. Independent prognostic value was found for IDH1/2 mutational status and ECOG performance status. n/a = not applicable.  ... 
doi:10.21996/knkr-p680 fatcat:ovbr6g36kzc5falkqndfsegrwi

The real-time molecular characterisation of human brain tumours during surgery using Rapid Evaporative Ionization Mass Spectrometry [REIMS] and Raman spectroscopy: a platform for precision medicine in neurosurgery

Babar Vaqas, Kevin O'Neill, Nelofar Syed, Zoltan Takats, Brain Tumour Research
2019
The systems identified normal versus tumour tissue, tumour grade, tumour type, tumour density and tissue status of key markers of gliomagenesis.  ...  A single centre prospective observational study of both modalities was designed involving a total of 75 patients undergoing craniotomy and resection of a range of brain tumours.  ...  ROC curve and AUC for the PLS-LDA model when predicting MGMT status.  ... 
doi:10.25560/75545 fatcat:p37jlgi5efghjhjnuauaeollve

Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011, pp 1-89

2011 Onkologie (Basel)  
The WHO classification will briefly be reviewed and the role of prognostic and predictive biomarkers including IDH-1 and MGMT will be discussed.  ...  Nevertheless there are differing observations concerning the predictive value of KRAS mutational status for patient survival.  ...  Anaemia incidence and prevalence in patients with cancer is high and significantly correlates with poor performance status.  ... 
doi:10.1159/000333299 fatcat:ciesjvjdxzds5fgtsxclqaovde

Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011, pp 90-184

2011 Onkologie (Basel)  
Analysis of RD was adjusted for the potential confounders FLIPI, performance status, R-containing induction and remission status.  ...  Mutations in isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) genes have recently been described as relatively frequent molecular lesions in gliomas and in acute myeloid leukemia (AML).  ...  Different parameters like TNM, performance status, nuclear grade or necrosis can help to predict the outcome in individual patients.  ... 
doi:10.1159/000333301 fatcat:rebrjglsybb7xn4lq53ouyjuci

Abstracts

2012 Journal of Thoracic Oncology  
In multivariate analysis only VS status was significant for PFS (p=0.011); for OS VS status (p=0.017) and PS (p=0.005) were significant.  ...  An interaction analysis adjusted for confounding variables revealed a significant interaction of VS status and treatment (arm A vs. Arm B) for PFS (p<0.001) and for OS (p=0.017).  ...  high grade gliomas.  ... 
doi:10.1097/jto.0b013e318269fc07 fatcat:vdv3ahsyibgbritt6r5443vvci
« Previous Showing results 1 — 15 out of 24 results